Phase I/II Study of Weekly Carfilzomib, Cyclophosphamide and Dexamethasone in Patients with Newly Diagnosed MM


Phase I/II Study of Weekly Carfilzomib, Cyclophosphamide and Dexamethasone in Patients with Newly Diagnosed MM
Slides from a presentation at ASH 2014 and transcribed comments from a recent interview with Ola Landgren, MD, PhD (2/9/15)
Palumbo A et al. Weekly carfilzomib, cyclophosphamide and dexamethasone (wCCd) in newly diagnosed multiple myeloma patients: A phase I-II study. Proc ASH 2014;Abstract 175.

Dr Landgren is Chief of the Myeloma Service at Memorial Sloan Kettering Cancer Center in New York, New York.